Selected Publications:
S Mohan, S Wang, G Coban, F Kural, S Chawla, D O’Rourke, H Poptani: Detection of Occult Neoplastic Infiltration in the Corpus Callosum and Prediction of Overall Survival in Patients with Glioblastoma using Diffusion Tensor Imaging European Journal of Radiology : 2019 .
Viaene AN, Zhang B, Martinez-Lage M, Xiang C, Tosi U, Thawani JP, Gungor B, Zhu Y, Roccograndi L, Zhang L, Bailey RL, Storm PB, O'Rourke DM, Resnick AC, Grady MS, Dahmane N: Transcriptome signatures associated with meningioma progression. Acta Neuropathol Commun 7 (1): 67,2019.
Caplan IF, Sullivan PZ, Kung D, O'Rourke DM, Choudhri O, Glauser G, Osiemo B, Goodrich S, McClintock SD, Malhotra NR: The LACE+ index as a predictor of 30-day readmission in a brain tumor population. World Neurosurg. 19 : pii: S1878-8750(19)30849-6,2019.
Liu T, Xu H, Huang M, Ma W, Saxena D, Lustig RA, Alonso-Basanta M, Zhang Z, O'Rourke DM, Zhang L, Gong Y, Kao GD, Dorsey JF, Fan Y.: Circulating Glioma Cells Exhibit Stem Cell-like Properties. Clin Cancer Res 78 (23): 6632-6642,2018.
Verma G, Chawla S, Mohan S, Wang S, Nasrallah M, Sheriff S, Desai A, Brem S, O'Rourke DM, Wolf RL, Maudsley AA, Poptani H.: Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. NMR Biomed : 2018.
Bagley SJ, Schwab RD, Nelson E, Viaene AN, Binder ZA, Lustig RA, O'Rourke DM, Brem S, Desai AS, Nasrallah MP.: Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma. J Neurooncol : 2018.
Wang S, O'Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrissette JJD, Plesa G, June CH, Brem S, Maloney E, Desai A, Wolf RL, Poptani H, Mohan S.: Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. British Journal of Cancer : 2018.
Bagley SJ, Hwang WT, Brem S, Linette GP, O'Rourke DM, Desai AS: RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. J Neurooncol : 2018.
Liu T, Ma W, Xu H, Huang M, Zhang D, He Z, Zhang L, Brem S, O'Rourke DM, Gong Y, Mou Y, Zhang Z, Fan Y: PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma Nature Communications 9 (1): 3439,2018.
Yin Y, Boesteanu, AC, Binder, ZA, Xu C, Reid RA, Rodriguez J L, Cook DR; Thokala, R, Blouch, K McGettigan-Croce B, Zhang L, Konradt Christoph, Cogdill, AP, Panjwani, MK; Jiang S, Migliorini, D, Dahmane N, Posey Jr, AD; June CH, Mason NJ, Lin, Z, Johnson, LA, O’Rourke, DM: Checkpoint blockade reverses anergy in IL13Rα2 humanized scFv based CAR T cells to treat murine and canine gliomas.
Molecular Therapy-Oncolytics 11 : 20-38,2018.